-
Nocturnal Enuresis Medication Market Forecast 2025-2034: Insights on Size, Growth, Trends & Competition
19 Jun 2025 11:19 GMT
… remote diagnosis and treatment, and better accessibility to medications.
Which Major … & Co. KG, Ferring Pharmaceuticals A/S, UroGen Pharma …
- By Drug Class: Desmopressin, Imipramine, Oxybutynin, Combined Pharmacotherapy, Antidepressants
- By …
-
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
29 May 2025 17:10 GMT
… .S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.’s ETON new … : Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month … designed to help patients access treatment. Eton Cares will offer co …
-
FDA approves Eton’s application for hydrocortisone oral solution
29 May 2025 13:34 GMT
… US Food and Drug Administration (FDA) approval as a … struggle with swallowing pills or have specific … FDA-approved hydrocortisone treatment for paediatric adrenocortical insufficiency.
Eton Pharmaceuticals … Office for the desmopressin oral solution formulation …
-
Brain Delivery Strategies for Biomacromolecular Drugs: Intranasal Administration
22 May 2025 15:04 GMT
… medications (ASMs) have been developed for epilepsy treatment.133 However, these drugs … peptides such as desmopressin, calcitonin and enkephalin … Artif Cells Nanomed Biotechnol. 2018;46(8):2088– … “”“Nose-to-Brain” drug delivery. Pharmaceutics. 2019;11(2):84. …
-
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
13 May 2025 20:41 GMT
… the U.S. Food and Drug Administration (FDA) Management to hold conference … oral solution of desmopressin under development for the treatment of central diabetes … Information As previously announced, Eton Pharmaceuticals will host its first quarter …
-
Eton Pharma submits NDA to US FDA for ET-600 for treatment of central diabetes insipidus
29 Apr 2025 11:31 GMT
… ) to the US Food and Drug Administration (FDA) for ET-600, Eton … oral solution of desmopressin under development for the treatment of central diabetes … Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading paediatric endocrinologists have long …
-
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
28 Apr 2025 10:50 GMT
… the U.S. Food and Drug Administration (FDA) for ET-600, Eton … oral solution of desmopressin under development for the treatment of central diabetes … Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading pediatric endocrinologists have long …
-
Nurse advocates for better support and treatments for POTS illness
26 Mar 2025 02:49 GMT
… there's no FDA-approved medication for POTS. There… isn't a magical pill, or magic procedure, that… Rao about treatment.
So, here is what the doctors recommend:
Take … position).
Desmopressin nasal is in a class of medications called antidiuretic …
-
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
18 Mar 2025 10:50 GMT
… formulation of desmopressin oral solution. … Orphan Drug Designation by the FDA, which … Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments …
—
5,380
Accrued Medicaid rebates
6,866
…
-
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript
19 Mar 2025 12:21 GMT
… efficient Salesforce efforts. Eton Pharmaceuticals, Inc. has also … ninety percent of doctors who treat this … pediatric endocrinology for appropriate treatment. Since there are … FDA-approved oral liquid formulation of desmopressin.
Currently, Desmopressin …